reason report
recap dani- boy pipe line call ind
bottom line evolut achn complement factor cfd
inhibitor platform gener encourag data danicopan
formerli follow believ superior
data excit investor possibl bid oral
administ drug may address complement-medi diseas
like paroxysm nocturn hemoglobinuria pnh share nearli
doubl sinc data announc link anticip investor
interest gain momentum ind file enter
clinic de-risk howev believ
upcom updat danicopan pnh
glomerulopathi potenti influenc investor
sentiment reiter op increas pt previous
opex revis
updat model adjust opex gain
clariti strategi model danicopan revenu pnh
thu long-term opex project adjust lower
pend addit new program -- other also
updat model reflect financi result announc recent
dcf discount rate
year price history/av daili volume mil achn
compani inform svb leerink llc research
ep
pleas refer page import disclosur price chart analyst certif
achn biopharmaceut compani portfolio oral
complement factor cfd inhibitor clinic develop lead candid
investig orphan complement-medi diseas paroxysm nocturn
hemoglobinuria pnh glomerulopathi although complement biolog remain
rel less well understood rare form diseas achn employ systemat
approach design cfd inhibitor program believ could creat meaning
sharehold valu manag demonstr favor efficaci safeti lead
cfd candid beyond compani leverag proprietari portfolio
cfd inhibitor identifi second gener cfd inhibitor achn
plan bring clinic asset show promis lower dose frequenc
alongsid increas potenc compani continu increas expertis complement
biolog believ favor posit expand clinic pipelin target broad
array complement-medi diseas near-term catalyst includ addit data pnh
larger market opportun possibl long term remain intrigu cfd
platform view next month import time valid achn approach
pt base discount cash flow dcf analysi incorpor two complement-
mediat diseas paroxysm nocturn hemolysis/pnh
current estim penetr pnh patient whose diseas well
control alxn soliri roughli treatment-nav pnh patient peak
ascrib probabl success po indic believ repres
peak sale approv assum peak penetr coincid expir
orphan drug exclus ode us order account potenti gener competit
also includ potenti revenu po reflect compani earli stage
develop peak sale achn complement inhibitor portfolio benefit
extens patent protect last whose extens could
strengthen longev revenu stream pre-commerci compani appli
discount rate termin growth rate consist similarli situat compani
coverag bold
risk valuat includ competit risk product receiv approv enter
commerci risk associ clinic trial regulatori review
research develop
chang cash
loss disp fix asset
prem purchas market secur
amort prem market secur
chang oper asset liabil
purchas fix asset
purchas market secur
matur market secur
proce issuanc stock
proce exercis warrant
payment defer financ cost
issuanc debt repay
discount rate/cost equiti
data readout phase ii poc trial mo dose
phase ii add-on soliri data pnh
end phase ii meet fda ema
